Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Delaying the Onset of Psoriatic Arthritis: Evidence, Limitations, and Treatment Strategies
Description
The talk reviews whether psoriasis treatment can delay or prevent psoriatic arthritis, arguing that “delay of onset” is a better framing than true prevention because risk exists across all psoriasis patients, with higher risk in those with obesity, severe disease, nail/scalp involvement, or subclinical imaging findings. A biologic model is described in which inflammatory cells and memory T cells move from skin to joints, though a newer study suggests macrophages may be more important than T cells in this transition. Evidence from large retrospective databases and prospective cohorts suggests IL-23 inhibitors may delay onset slightly more than IL-17 or TNF inhibitors, but the speaker emphasizes major limitations, especially confounding and protopathic bias, so these studies cannot justify changing clinical practice. A key takeaway is that controlling psoriasis itself may matter more than choosing a specific agent, and ongoing prospective studies in enriched, subclinical populations may help answer the question more reliably. Overall, the speaker concludes that current evidence is intriguing but insufficient, and the safest strategy today is to treat psoriasis well while awaiting better prospective data.
View moreConclusions
- The presentation concludes that it is still unproven whether psoriasis therapy can prevent or delay psoriatic arthritis, so treatment choices should not yet be changed on the basis of these data.
- If prevention is possible, it is more realistically framed as delaying onset in high-risk psoriasis patients rather than truly preventing psoriatic arthritis.
- Observational studies and large claims databases repeatedly suggest that IL-23 inhibitors may be associated with a lower or slower incidence of psoriatic arthritis than other biologic classes, but these findings are heavily limited by bias and confounding.
- The strongest apparent predictor in the reviewed data may be how well psoriasis itself is controlled, rather than the specific biologic mechanism chosen.
- The biology of progression from skin disease to joint disease remains unresolved, with competing hypotheses involving memory T cells versus myeloid cells/macrophages.
- Prospective studies are needed to answer the question definitively, but they are difficult because incident psoriatic arthritis is relatively rare and requires enriched, long-term cohorts.
- The ongoing preventive trial in high-risk patients will be important, but current evidence is not sufficient to claim that any agent reliably prevents psoriatic arthritis.
- Mease P. et al. Maui Derm 2022, #11400.
- Scher JU, et al. Nat Rev Rheumatol 2019;15:153–66.
- Labao B. Frontiers in Medicine. 2024.
- Mehta et al, J Invest Dermatol, 2021.
- Raimondo MG et al., Nat Immunol 2026;27:35–47.
- Singla S, et al. Lancet Rheumatol 2023;5:e200–7.
- Strober B, et al. EADV 2023, FC08.8. Sponsored by AbbVie, Inc.
- Al-Janabi A, et al. EADV 2025, P3713.
- Strober B, et al. AAD 2025, P63027.
- Haberman et al., BMJ Open 2022, ClinicalTrials.gov NCT05004727, and Janssen Scientific Affairs LLC.